Core Viewpoint - The company has acknowledged the stock price trends and reassured that its operational status is normal, with no undisclosed significant matters [2] Group 1 - The company is actively monitoring its stock price movements and has confirmed that its internal management and business operations are proceeding in an orderly manner [2] - The company emphasizes its commitment to fulfilling information disclosure obligations in accordance with relevant regulations, ensuring that information is truthful, accurate, complete, and timely [2] - The stock price is influenced by various factors including macroeconomic conditions, market environment, industry dynamics, and investor sentiment [2] Group 2 - The company plans to continue focusing on its core business and aims to enhance operational performance to create value for investors [2]

Core Viewpoint - Aokai Co., Ltd. provides pharmaceutical-grade polyethylene glycol (PEG) raw materials and excipients to hundreds of formulation companies in China, primarily used in various drug forms such as injections, oral, and rectal preparations [2] Group 1: Company Overview - Aokai's PEG products are mainly utilized by pharmaceutical companies focusing on cardiovascular, viral cold, and constipation treatments [2] - The company adheres to information disclosure regulations and will provide updates on business and technological advancements through official announcements [2] Group 2: Intellectual Property and Client Structure - Information regarding the patent status of pharmaceutical-grade PEG is publicly available on platforms like the National Intellectual Property Administration [2] - Due to commercial confidentiality, Aokai is unable to disclose detailed information about its client structure to protect the interests of the company and its partners [2]

证券日报网讯奥克股份9月17日在互动平台回答投资者提问时表示，公司PEO固态电解质领域具有基础 的技术研发储备，技术规划主要围绕提升性能以适配下游需求推进。目前相关材料暂处研发阶段，商业 化时间需结合技术成熟度、下游应用进展等综合确定，达到披露标准后将及时公告，具体进展请以公告 为准。 （文章来源：证券日报） ...

Core Viewpoint - Hubei's capital market is accelerating, with five companies, including Jihachang, applying for IPOs and receiving inquiries from the Beijing Stock Exchange [1] Company Overview - Jihachang, established on August 25, 2005, focuses on the R&D, production, and sales of specialty functional materials related to surface and interface treatment [5] - The company is recognized as a vice-chairman unit of the China Surface Engineering Association and has received multiple awards and patents [5] Financial Performance - Jihachang's revenue and net profit from 2022 to 2024 are projected to be 427 million, 438 million, and 517 million CNY, and 56.09 million, 56.21 million, and 56.35 million CNY respectively [9] - The revenue growth rates for 2023 and 2024 are 2.66% and 18.05%, while net profit growth rates are 0.22% and 0.24%, indicating stable revenue but stagnant profit [9] Market Position and Comparison - Jihachang's performance diverges from comparable companies, many of which are experiencing declining profits or losses [11] - In 2024, Jihachang's net profit margin is projected at 10.89%, significantly higher than the industry average of -63.15% [13] Investment Plans - The company plans to raise 290 million CNY through its IPO for various projects, including a 12,000-ton photovoltaic materials project and a 2,000-ton integrated circuit plating chemicals project [20] - The total investment for these projects is estimated at 296.34 million CNY, with a significant portion allocated to expanding production capacity [7] Capacity Utilization Concerns - Jihachang's capacity utilization rates are declining, with overall rates projected at 72.02%, 73.51%, and 69.03% from 2022 to 2024 [22] - The company is facing questions regarding the logic of expanding production amid declining capacity utilization and potential industry overcapacity [23] Related Party Transactions - Jihachang has a close relationship with its second-largest shareholder, Aoke Co., which holds a 37.71% stake [25] - The two companies have collaborated on projects, raising concerns about the independence and integrity of Jihachang's operations [26]

奥克股份（300082.SZ）9月17日在投资者互动平台表示，公司PEO固态电解质领域具有基础的技术研发 储备，技术规划主要围绕提升性能以适配下游需求推进。目前相关材料暂处研发阶段，商业化时间需结 合技术成熟度、下游应用进展等综合确定，达到披露标准后将及时公告，具体进展请以公告为准。 （记者 王瀚黎） 每经AI快讯，有投资者在投资者互动平台提问：咱们公司在 PEG 和 PEO 这两块的布局，能不能结合半 固态或者复合固态电解质来解说一下？ ...

证券日报网讯奥克股份（300082）9月15日在互动平台回答投资者提问时表示，公司始终密切关注聚乙 二醇在各领域的应用动态。目前，产品在医药原料药、锂电新能源及日化等领域已有规模化应用。若有 新领域、新应用等的重大突破且符合披露标准，公司将依法依规及时披露。 ...

Group 1 - The company has confirmed that it is currently capable of producing and selling battery-grade polyethylene glycol and carbonate series products, including EC and DMC [2]

Group 1 - The company, Aoke Co., announced on September 15 that it is currently capable of producing and selling battery-grade polyethylene glycol and carbonate series products, including EC and DMC [2]

Group 1 - The company, Aoke Co., Ltd. (300082), is currently in the application research and development stage for its PEO (Polyethylene Oxide) [1] - Aoke has laboratory samples of 400,000 molecular weight PEO, but further modification and development work is required for its use in solid-state electrolytes [1]

Core Viewpoint - Aok shares highlighted the non-toxic and non-irritating properties of polyethylene glycol (PEG) products, emphasizing their wide applications in various industries, including pharmaceuticals and daily chemicals [1] Group 1: Product Characteristics - PEG products are characterized by good water solubility and compatibility with many organic components [1] - The products exhibit excellent lubricating, moisturizing, dispersing, adhesive, antistatic, and softening properties [1] Group 2: Industry Applications - Aok's PEG products have achieved large-scale applications in pharmaceutical excipients, raw materials for drugs, lithium battery new energy, and daily chemicals [1] - In the pharmaceutical sector, PEG is utilized in products such as Danshen dripping pills, rapid heart rescue pills, and injectables [1]